← Eichor
Study identifier: NCT06863272 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Condition: Castration-Resistant Prostatic Cancer · Metastasis  ·  Sponsor: Merck Sharp & Dohme LLC

PhasePhase 1/Phase 2
Planned participants360
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the study treatment and if people tolerate it. * A safe dose level of I-DXd that can be used with other treatments. * Participant levels of prostate specific antigen (PSA) during treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Toll Free Number  ·  1-888-577-8839  ·  Trialsites@msd.com

Always discuss trial participation with your own doctor first.

Locations (82)

UCLA Hematology & Oncology ( Site 0003)Los Angeles, California, United StatesRecruiting
University of California-Irvine Medical Center ( Site 0016)Orange, California, United StatesRecruiting
UCSF Medical Center at Mission Bay ( Site 0034)San Francisco, California, United StatesRecruiting
MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)Washington D.C., District of Columbia, United StatesRecruiting
University of Michigan ( Site 0021)Ann Arbor, Michigan, United StatesRecruiting
Memorial Sloan Kettering Cancer Center ( Site 0006)New York, New York, United StatesRecruiting
UPMC Hillman Cancer Center ( Site 0014)Pittsburgh, Pennsylvania, United StatesRecruiting
The West Clinic, PLLC dba West Cancer Center ( Site 0005)Germantown, Tennessee, United StatesRecruiting
Fred Hutchinson Cancer Center ( Site 0013)Seattle, Washington, United StatesRecruiting
Instituto Alexander Fleming ( Site 0202)Ciudad Autónoma de Buenos Aires, Buenos Aires, ArgentinaRecruiting
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200)La Rioja, ArgentinaRecruiting
Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)Macquarie University, New South Wales, AustraliaRecruiting

+ 70 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06863272